Financial Performance - The company's operating revenue for Q1 2025 was CNY 1,394,250,050.21, representing a 1.53% increase compared to CNY 1,373,251,921.93 in the same period last year[8] - Net profit attributable to shareholders for Q1 2025 was CNY 156,590,188.54, a 1.00% increase from CNY 155,040,262.39 year-on-year[8] - The net profit after deducting non-recurring gains and losses increased by 20.27% to CNY 188,891,082.26 from CNY 157,052,354.18 in the previous year[8] - The total operating profit for the current period is 178,980,342.21, a decrease of 9.4% from 196,847,737.66 in the previous period[34] - Net profit for the current period is 156,169,189.45, showing a slight increase of 1.0% compared to 154,597,836.94 in the previous period[34] - The company's net profit margin improved, with net profit for the period showing a significant recovery compared to the previous period, although specific figures were not disclosed[33] Cash Flow - The net cash flow from operating activities decreased by 38.21% to CNY 544,031,931.35, down from CNY 880,453,882.15 in the same period last year[8] - The cash flow from operating activities is 544,031,931.35, down 38.3% from 880,453,882.15 in the previous period[39] - The net cash flow from investing activities saw a significant decline of 297.07%, resulting in a negative cash flow of ¥257,551,999.87, mainly due to increased purchases of financial products[19] - The cash flow from investment activities shows a net outflow of 257,551,999.87, compared to a net inflow of 130,688,287.99 in the previous period[40] - The net cash flow from financing activities increased by 103.37% to ¥22,602,544.83, as the amounts borrowed and repaid remained relatively stable compared to the previous year[19] - Net cash flow from financing activities was $22,602,544.83, a significant improvement from a negative $670,833,066.44 in the previous period[41] Assets and Liabilities - Total assets at the end of the reporting period were CNY 17,545,801,889.02, reflecting a 1.17% increase from CNY 17,343,523,964.97 at the end of the previous year[8] - Total liabilities increased to CNY 5,205,766,284.88 from CNY 5,141,403,413.17, reflecting an increase of approximately 1.2%[31] - The equity attributable to shareholders increased by 1.14% to CNY 12,287,013,002.74 from CNY 12,148,672,778.24 year-on-year[8] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 28,367, with the largest shareholder, Shenzhen Lerun Technology Co., Ltd., holding 32.31% of shares[22] - The top ten shareholders collectively hold significant stakes, with the second-largest shareholder, Xiamen Jintian Soil Investment Partnership, holding 27.81%[22] - The largest shareholder, Shenzhen Lerun Technology Co., Ltd., has a total of 474,029,899 shares, while the second-largest holds 408,041,280 shares[23] - The company has not reported any changes in the participation of the top ten shareholders in margin trading or securities lending activities compared to the previous period[24] - There are no preferred shareholders or related changes reported in the current period[24] Investment and Expenses - The company reported a significant increase in investment income, rising by 132.79% to CNY 20,292,064.76 from a loss of CNY 61,890,173.43 in the previous year[17] - Research and development expenses were CNY 39,993,799.57, up from CNY 35,294,968.25, indicating an increase of about 19.2%[33] - The company experienced a 190.08% decrease in financial expenses, resulting in a gain of CNY 56,508,230.69 due to foreign exchange gains[17] - The deferred income increased by 65.95% to CNY 45,279,690.29, primarily due to government subsidies received during the reporting period[15] - The company reported a substantial increase in asset disposal income, which rose by 4404.34% to CNY 1,288,820.50 from CNY 28,612.85 in the previous year[17] Inventory and Receivables - Accounts receivable increased to CNY 1,382,358,370.19 from CNY 1,178,554,557.22, showing a rise of about 17.3%[28] - Inventory decreased to CNY 4,952,734,323.44 from CNY 5,393,947,174.38, a decline of approximately 8.2%[28] Cash and Equivalents - The company's cash and cash equivalents at the end of the period were CNY 2,000,842,827.21, up from CNY 1,689,041,495.34 at the beginning of the period, indicating a growth of approximately 18.4%[28] - The ending balance of cash and cash equivalents was $1,740,464,878.53, down from $2,108,383,601.96 in the prior period[41] - The net increase in cash and cash equivalents was $318,638,044.68, slightly lower than $342,738,890.08 in the previous period[41] Other Financial Metrics - The total comprehensive income for the current period is 137,915,052.34, a decrease of 8.1% from 150,135,056.48 in the previous period[36] - Basic and diluted earnings per share for the current period are both 0.1067, an increase from 0.1057 in the previous period[36] - The company recorded a foreign exchange loss of 47,399,165.67 in other comprehensive income, contrasting with a gain of 3,002,651.97 in the previous period[35] - The company received cash from sales of goods and services totaling 1,327,258,705.88, down 11.1% from 1,493,180,137.55 in the previous period[39] - The company reported a decrease in cash received from other operating activities to 47,510,298.94, down from 97,379,140.23 in the previous period[39] - The company’s net impairment loss on assets decreased significantly to 44,094.91 from 33,754,398.03 in the previous period[34] Audit and Reliability - The first quarter report was not audited, indicating potential limitations in financial reliability[42]

一、主要会计数据和财务指标 三、分红送配方案情况 | 报告期指标 | 2025年一季报 | 2024年一季报 | 本年比上年增减(%) | 2023年一季报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.1067 | 0.1057 | 0.95 | 0.0453 | | 每股净资产（元） | 8.37 | 8.22 | 1.82 | 8.43 | | 每股公积金(元) | 4 | 4.33 | -7.62 | 3.99 | | 每股未分配利润(元) | 2.86 | 2.41 | 18.67 | 2.99 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 13.94 | 13.73 | 1.53 | 13.01 | | 净利润(亿元) | 1.57 | 1.55 | 1.29 | 0.67 | | 净资产收益率(%) | 1.28 | 1.29 | -0.78 | 0.54 | 本次公司不分配不转赠。 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 125360.0 ...

Revenue and Profit - The company's revenue for Q1 2025 was ¥1,394,250,050.21, representing a year-over-year increase of 1.53% compared to ¥1,373,251,921.93 in the same period last year[5]. - Net profit attributable to shareholders was ¥156,590,188.54, a slight increase of 1.00% from ¥155,040,262.39 in the previous year[5]. - The net profit after deducting non-recurring gains and losses increased by 20.27% to ¥188,891,082.26 from ¥157,052,354.18 year-over-year[5]. - Total operating revenue for the current period reached ¥1,394,250,050.21, an increase of 1.4% compared to ¥1,373,251,921.93 in the previous period[23]. - Net profit for the current period was ¥156,169,189.45, slightly higher than ¥154,597,836.94 from the previous period, indicating a growth of about 1%[24]. - Earnings per share (EPS) for the current period was ¥0.1067, compared to ¥0.1057 in the previous period, showing an increase of 0.9%[25]. Cash Flow - The net cash flow from operating activities decreased significantly by 38.21% to ¥544,031,931.35 from ¥880,453,882.15 in the same period last year[5]. - Cash inflow from operating activities totaled ¥1,501,965,061.54, a decrease from ¥1,664,646,503.27 in the previous period, representing a decline of approximately 9.7%[26]. - The net cash flow from operating activities was $544,031,931.35, a decrease of 38.2% compared to $880,453,882.15 in the previous period[27]. - Total cash outflow from operating activities amounted to $957,933,130.19, up from $784,192,621.12, indicating a 22.1% increase[27]. - Cash inflow from investment activities totaled $605,376,122.24, compared to $441,112,963.21, reflecting a 37.3% increase[27]. - The net cash flow from investment activities was -$257,551,999.87, a decline from $130,688,287.99 in the previous period[27]. - Cash inflow from financing activities was $750,396,287.53, down from $835,834,333.10, representing a decrease of 10.2%[27]. - The net cash flow from financing activities was $22,602,544.83, a significant improvement from -$670,833,066.44 in the previous period[27]. - The total cash and cash equivalents at the end of the period were $1,740,464,878.53, down from $2,108,383,601.96[27]. - The cash and cash equivalents increased by $318,638,044.68 during the period, compared to an increase of $342,738,890.08 in the previous period[27]. Assets and Liabilities - Total assets at the end of the reporting period were ¥17,545,801,889.02, reflecting a 1.17% increase from ¥17,343,523,964.97 at the end of the previous year[5]. - The company's total liabilities amounted to ¥5,205,766,284.88, compared to ¥5,141,403,413.17 in the previous period, reflecting an increase of about 1.25%[21]. - Total equity attributable to shareholders reached ¥12,287,013,002.74, up from ¥12,148,672,778.24, marking an increase of approximately 1.14%[21]. - Total current assets amount to 9,873,944,183.93 RMB, an increase from 9,621,274,306.15 RMB at the beginning of the period[19]. - Total assets amount to 17,545,801,889.02 RMB, compared to 17,343,523,964.97 RMB at the beginning of the period[20]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 28,367[16]. - The largest shareholder, Shenzhen Lerun Technology Co., Ltd., holds 32.31% of shares, totaling 474,029,899 shares[16]. - The second-largest shareholder, Xiamen Jintian Investment Partnership, holds 27.81%, totaling 408,041,280 shares[16]. Other Financial Metrics - The company's basic earnings per share (EPS) was ¥0.1067, up 0.95% from ¥0.1057 in the same period last year[5]. - The weighted average return on equity (ROE) slightly decreased to 1.28% from 1.29% year-over-year[5]. - The company reported a decrease in financial expenses, with a net financial cost of -¥56,508,230.69 compared to ¥62,732,180.93 in the previous period[24]. - The company experienced a decrease in comprehensive income, totaling ¥137,915,052.34 compared to ¥150,135,056.48 in the previous period, a decline of about 8%[25]. - The company reported a significant increase in deferred income by 65.95% to ¥45,279,690.29 due to government subsidies received during the reporting period[11]. - Deferred income increased to ¥45,279,690.29 from ¥27,284,974.87, indicating a significant rise of approximately 65.9%[21]. - The company has a total of 366,727,264.95 RMB in long-term equity investments[20]. - The company’s goodwill stands at 2,353,689,028.00 RMB, a slight decrease from 2,357,033,547.26 RMB[20]. - Inventory decreased to 4,952,734,323.44 RMB from 5,393,947,174.38 RMB[20]. - Short-term borrowings are reported at 1,819,531,746.74 RMB, slightly down from 1,838,944,224.03 RMB[20]. - The company paid $225,883,127.82 to employees, an increase from $182,063,990.65 in the previous period[27]. - The company reported a total tax payment of $71,329,471.04, up from $61,136,636.42, indicating a 19.8% increase[27].

Core Viewpoint - The approval of Ivenoxin (enoxaparin sodium injection) by the South African Health Products Regulatory Authority is expected to enhance the sales of the product in the South African market and increase the company's global market share [1] Company Summary - The company, Haiprui (002399), announced that its wholly-owned subsidiary, Tiandao Pharmaceutical, has received the approval notification for enoxaparin sodium injection [1] - The product is available in various specifications: 0.2ml:20mg, 0.4ml:40mg, 0.6ml:60mg, 0.8ml:80mg, and 1.0ml:100mg [1] - The indications for the product include thrombosis prevention before and after surgery, reduction of thrombotic risk in acute diseases, and treatment of deep vein thrombosis [1] - The license for the product is valid for five years [1] Industry Summary - The approval is anticipated to boost the company's enoxaparin sodium formulation sales in South Africa, contributing positively to its market presence [1]

证券代码：002399 证券简称：海普瑞 公告编号：2025-021 根据外部市场环境结合公司全球业务发展的需求，经公司于2025年4月24日 召开的第六届董事会第十五次会议审议通过，决定对原增资方案进行调整，将原 增资金额1.05亿美元调整为3,192万美元，其余内容不变。 调整后的增资金额在公司董事会决策权限内，无需提交股东大会审议批准。 上述调整增资方案的事项不构成关联交易，亦不构成《上市公司重大资产重组管 理办法》规定的重大资产重组。 一、增资标的的基本情况 （一）多普乐 关于向全资子公司天道医药（香港）有限公司增资 的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 重要内容提示 经深圳市海普瑞药业集团股份有限公司（以下简称"公司"或"海普瑞"） 于2021年12月10日召开的第五届董事会第十五次会议审议通过，公司决定使用H 股募集资金1.05亿美元以逐层增资的方式向全资子公司天道医药（香港）有限公 司（以下简称"香港天道"）增资，用于欧盟及其他全球市场拓展销售及营销网 络以及基础设施的建设。具体增资路径为海普瑞向其全资子公司深圳市多普乐实 ...

深圳市海普瑞药业集团股份有限公司（以下简称"公司"）的全资孙公司深圳 市天道医药有限公司（以下简称"天道医药"）近期收到南非卫生产品管理局（South African Health Products Regulatory Authority）签发的依诺肝素钠注射液批准通知。 现将相关情况公告如下： （五）适应症： （六）许可有效期：五年 证券代码： 002399 证券简称：海普瑞 公告编号：2025-024 深圳市海普瑞药业集团股份有限公司 关于依诺肝素钠注射液获得南非药品注册批件的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、基本情况 《证券时报》《证券日报》《中国证券报》《上海证券报》和巨潮资讯网 （www.cninfo.com.cn）为公司指定信息披露媒体，公司所有信息均以在上述指定媒 体刊登的信息为准。公司将严格按照有关法律法规的规定和要求，认真履行信息披 露义务，及时做好信息披露工作。 公司郑重提请投资者注意：投资者应充分了解股票市场风险及公司定期报告 中披露的风险因素，审慎决策、理性投资。 特此公告 深圳市海普瑞药业集团股份有限公司 二 ...

Financial Performance - Total revenue for the year ended December 31, 2024, was approximately RMB 5,258.9 million, a decrease of 3.2% from RMB 5,431.0 million in 2023[3] - Gross profit for the year was approximately RMB 1,739.3 million, with a gross margin of 33.1%, compared to a gross profit of RMB 940.9 million and a margin of 17.3% in 2023[3] - Profit attributable to equity holders of the parent company was approximately RMB 646.7 million, a significant recovery from a loss of RMB 783.3 million in 2023[3] - The net profit turned positive, amounting to approximately RMB 624.9 million, with profit attributable to equity holders of the company at approximately RMB 646.7 million[10] - The pre-tax profit for the group was RMB 640,893,000 in 2024, down from RMB 744,375,000 in 2023, indicating a decline of about 14%[68] - The total income tax expense for the year was RMB 101,311,000 in 2024, compared to a tax credit of RMB 126,175,000 in 2023[71] - Basic and diluted earnings per share were RMB 0.44, compared to a loss per share of RMB 0.53 in 2023[34] Revenue Breakdown - The sales revenue from the formulation business was approximately RMB 2,986.1 million, with a gross margin of 31.8%, compared to RMB 2,979.0 million and a margin of 43.1% in 2023[3] - The API business generated sales revenue of approximately RMB 1,065.7 million, with a gross margin of 38.6%, compared to RMB 1,307.3 million and a margin of -42.8% in 2023[3] - The CDMO business reported sales revenue of approximately RMB 1,033.8 million, with a gross margin of 32.9%, up from RMB 967.0 million and a margin of 22.0% in 2023[3] - The Heparin value chain business generated sales revenue of approximately RMB 4,051.8 million, a year-on-year decrease of about 5.5%[12] - The group's API business sales revenue was approximately RMB 1,065.7 million, a year-on-year decrease of about 18.5%, while sales volume increased by approximately 10.8% compared to the same period in 2023, with a gross margin of approximately 38.6%[15] - CDMO services revenue increased by 6.9% to approximately RMB 1,033.8 million, contributing 19.7% to total revenue[26] Asset and Liability Management - Non-current assets totaled RMB 7,722.3 million, a decrease from RMB 8,599.1 million in 2023[6] - Current assets decreased to RMB 9,621.3 million from RMB 10,604.3 million in 2023, primarily due to a reduction in inventory[6] - Current liabilities decreased to RMB 3,699.2 million from RMB 4,986.2 million in 2023, reflecting improved liquidity management[6] - Total assets as of December 31, 2024, were approximately RMB 17,343.5 million, compared to RMB 19,203.4 million in 2023, with a debt-to-asset ratio of about 29.6%[40] - The total liabilities for the year ended December 31, 2024, were RMB 5,141,403,000, down from RMB 7,215,040,000 in 2023, reflecting a reduction of approximately 28.73%[54][56] Cash Flow and Financing - The company's cash flow from operating activities increased by approximately 451.0% to about RMB 2,194.1 million, compared to approximately RMB 398.2 million in 2023[9] - Financing costs decreased by approximately RMB 82.9 million to about RMB 145.2 million, a reduction of about 36.3% compared to RMB 228.1 million in 2023[30] - Cash and bank balances as of December 31, 2024, were approximately RMB 1,421.8 million, down from RMB 1,765.6 million in 2023[36] - Interest-bearing bank and other borrowings amounted to approximately RMB 3,448.2 million as of December 31, 2024, down from RMB 5,434.6 million in 2023[42] Dividends and Shareholder Information - The board proposed a final cash dividend of RMB 2.5 per share, with a payout ratio of 56.7%, compared to no dividend in 2023[3] - Proposed final dividend for 2024 is RMB 0.25 per share, totaling RMB 366,824 thousand, compared to no dividend in 2023[75] - The annual general meeting for the year 2024 will be held on May 22, 2025, with a notice to be published in due course[86] Research and Development - The group incurred research and development costs of RMB 212,036,000 in 2024, an increase of 16% from RMB 182,433,000 in 2023[68] - The candidate drug H1710 received approval for clinical trials from the National Medical Products Administration, indicating progress in the development of a new cancer treatment[18] - Oregovomab, a candidate drug for advanced ovarian cancer, is undergoing patient survival follow-up after a mid-term analysis of its Phase III clinical trial did not meet expected goals[19] - AR-301, a monoclonal antibody targeting Staphylococcus aureus, has received Fast Track designation from the FDA and orphan drug status from the EMA, with plans for a second Phase III study based on promising data in specific patient groups[20] Market Strategy and Operations - The company is focusing on enhancing its business capabilities and operational quality while optimizing its business structure to improve sales growth and operating profit[9] - The company plans to continue its globalization strategy, deepening its market presence in Europe, China, the United States, and other non-European and American markets[9] - The group is actively adjusting market strategies to cope with competitive pressures, focusing on maintaining price systems and enhancing product competitiveness[15] - The group is expanding its market coverage and deepening existing customer relationships while actively developing new customer bases in the CDMO sector[16] Compliance and Governance - The audit committee reviewed the consolidated annual performance for the year ending December 31, 2024, and confirmed compliance with relevant accounting standards and regulations[90] - Ernst & Young confirmed that the financial figures in the preliminary announcement align with the consolidated financial statements for the year ending December 31, 2024[91] - The company has not made any significant acquisitions or disposals of subsidiaries, associates, or joint ventures during the reporting period[81]

Financial Performance - The company's operating revenue for 2024 was ¥5,280,713,410.80, a decrease of 3.03% compared to ¥5,445,572,060.12 in 2023[6]. - The net profit attributable to shareholders for 2024 was ¥646,741,666.49, representing a significant increase of 182.57% from a loss of ¥783,258,039.42 in 2023[6]. - The cash flow from operating activities reached ¥2,194,132,237.51, marking a substantial increase of 450.99% compared to ¥398,215,676.99 in 2023[6]. - Basic earnings per share for 2024 were ¥0.4408, a turnaround from a loss of ¥0.5338 in 2023, reflecting an increase of 182.58%[6]. - The total assets at the end of 2024 were ¥17,343,523,964.97, a decrease of 9.69% from ¥19,203,415,131.24 at the end of 2023[6]. - The company reported a weighted average return on equity of 5.39% for 2024, an improvement of 11.99% from -6.60% in 2023[6]. - The company experienced a significant increase in net profit excluding non-recurring gains and losses, which was ¥253,544,139.42 in 2024 compared to a loss of ¥779,841,459.91 in 2023, an increase of 132.51%[6]. Dividend Distribution - The company plans to distribute a cash dividend of RMB 2.50 per 10 shares to all shareholders, based on a total of 1,467,296,204 shares[5]. - The cash dividend plan for 2024 proposes a distribution of ¥366,824,051, with a per-share dividend of ¥2.50 based on a total share capital of 1,467,296,204 shares[157]. - The company will not distribute cash dividends or issue bonus shares for the 2023 fiscal year, as approved in the shareholder meeting[155]. Business Operations - The company has not reported any changes in its main business operations since its listing[20]. - The company operates under the supervision of the National Medical Products Administration and adheres to Good Manufacturing Practices (GMP)[15]. - The company's main business includes the heparin industry chain, biopharmaceutical CDMO, and innovative drug investment, development, and commercialization[34]. - The heparin product line includes enoxaparin sodium preparations and heparin sodium raw materials, with a focus on high-quality and effective medications[35]. - The company has developed approximately 200 different molecular structures in the CDMO sector, demonstrating strong delivery records[38]. - The company provides comprehensive CDMO services, including development and cGMP manufacturing for biopharmaceuticals[43]. Market and Economic Environment - The company faced challenges in the global economy, with the IMF projecting global growth rates of 3.2% and 3.3% for 2024 and 2025 respectively[31]. - The company noted that the European economy is under pressure due to energy price fluctuations and geopolitical risks, impacting overall growth[31]. - The Asian market showed mixed performance, with China maintaining growth resilience despite internal demand weakening, while India is expected to exceed a growth rate of 6%[31]. - The company has seen a 5% year-on-year growth in GDP, indicating a positive economic environment for its operations[33]. Research and Development - R&D expenses increased by 16.23% to CNY 212,035,640.41, primarily due to increased investment in research projects[77]. - The company aims to enhance product quality through advanced research projects, including the synthesis of heparin precursors and polysaccharides[79]. - The company plans to accelerate the drug development process for RVX-208, which has received breakthrough therapy designation from the FDA[65]. - The company is committed to optimizing organizational structure and resource allocation to improve operational efficiency and profitability[111]. Risk Management - The company has detailed its future risks and corresponding mitigation strategies in the report[5]. - The company faces risks associated with new drug development, including potential failures during clinical trials, and will continue to manage resources effectively to advance its pipeline[117]. - The company faces significant foreign exchange risk due to major revenues coming from overseas markets, primarily settled in euros and US dollars, which may lead to substantial exchange gains or losses[118]. - The company has established a financial derivatives trading management system to mitigate risks associated with derivative transactions[100]. Corporate Governance - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[125]. - The company maintains a transparent information disclosure system, ensuring all investors have equal access to information[127]. - The company has implemented a strict insider information management system, with no reported insider trading incidents during the reporting period[128]. - The company actively engages with investors to enhance understanding and communication, adhering to investor relations management regulations[127]. Environmental Compliance - The company strictly adhered to multiple environmental protection laws and standards during its operations, including the Air Pollution Prevention and Control Law[169]. - The company holds valid pollution discharge permits for its facilities, with the latest permit for the Pingshan plant valid until October 29, 2029[170]. - The company reported a total emission of VOCs at 2.979 tons per year, which is within the regulatory limits[171]. - The company has established comprehensive wastewater and waste gas treatment facilities, ensuring that wastewater discharge is below the total amount approved by the discharge permit[175]. Employee and Management Structure - The total number of employees at the end of the reporting period is 1,926, with 839 in the parent company and 1,087 in major subsidiaries[150]. - The professional composition includes 680 production personnel, 123 sales personnel, 787 technical personnel, 64 financial personnel, and 272 administrative personnel[150]. - The company emphasizes a competitive and fair compensation policy, aligning employee remuneration with performance and market standards[152]. - The company has a performance evaluation system for determining the remuneration of directors and senior management[141].

证券代码：002399 证券简称：海普瑞 公告编号：2025-017 深圳市海普瑞药业集团股份有限公司 第三期员工持股计划（修订稿） 摘要 2025 年 03 月 声明 本公司及董事会全体成员保证本员工持股计划内容真实、准确和完整，不存 在虚假记载、误导性陈述或重大遗漏。 特别提示 1、深圳市海普瑞药业集团股份有限公司第三期员工持股计划（以下简称"本 员工持股计划"）系深圳市海普瑞药业集团股份有限公司（以下简称"公司"或 "海普瑞"）依据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《关于上市公司实施员工持股计划试 点的指导意见》（以下简称"《指导意见》"）及《中小企业板信息披露业务备忘录 第 7 号：员工持股计划》（以下简称"《备忘录 7 号》"）等有关法律、行政法规、 规章和规范性文件以及《公司章程》的规定制定。 2、本期员工持股计划遵循公司自主决定、员工自愿参加的原则，不存在摊 派、强行分配等强制员工参加本员工持股计划的情形。 3、本期员工持股计划拟募集资金总额为 8,700.00 万元，最终募集资金总额 以实际募资总额为准。资金来源为员工自筹 ...

Financial Performance - The company expects a net profit attributable to shareholders of between 58.9 million and 71.1 million yuan for 2024, a significant recovery from a loss of 78.3 million yuan in the previous year[2] - The net profit after deducting non-recurring gains and losses is projected to be between 21.4 million and 31.2 million yuan, compared to a loss of 77.98 million yuan in the same period last year[2] - Basic earnings per share are anticipated to be between 0.4014 yuan and 0.4846 yuan, recovering from a loss of 0.5338 yuan per share in the previous year[2] Market Conditions - The heparin industry chain's operating environment has improved, with a gradual recovery in market demand, leading to growth in sales of the main product, enoxaparin sodium, across various markets[4] - The global demand for heparin API has improved year-on-year, with an increase in export volume from China, although the average export price has significantly decreased due to lower raw material prices[4] Business Development - The company's CDMO business continues to recover, strengthening strategic partnerships with existing clients and exploring new customer groups to enhance revenue and profitability[5] - The company has optimized its external investment strategy, achieving significant progress and good investment returns during the reporting period[5]